Related Experiment Video
Updated: May 28, 2026

Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding
Published on: September 21, 2011
Pharmacodynamics of glucocorticoids.
C Strehl1, C M Spies, F Buttgereit
1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany. cindy.strehl@charite.de
Glucocorticoids (GCs) treat inflammatory diseases but cause side effects. Understanding their genomic and non-genomic actions is key to improving the GC risk-benefit balance for patients.
Area of Science:
- Pharmacology
- Immunology
- Molecular Biology
Background:
- Exogenous glucocorticoids (GCs) are widely used for their potent anti-inflammatory and immunosuppressive properties in treating various rheumatic and inflammatory conditions.
- GCs act through diverse mechanisms, including genomic and non-genomic pathways, influencing immune cells, tissues, and organs in a dose-dependent manner.
- Despite therapeutic benefits, GCs exhibit pleiotropic effects, leading to significant adverse effects like metabolic disturbances and osteoporosis, particularly with prolonged or high-dose use.
Purpose of the Study:
- To elucidate the complex molecular mechanisms underlying both the beneficial and adverse effects of glucocorticoids.
- To explore the dose-dependency of genomic and non-genomic GC actions.
- To identify strategies for optimizing the therapeutic risk-benefit ratio of glucocorticoid treatments.
Main Methods:
- Review of established knowledge on classical genomic (cGCR activation) and non-genomic mechanisms (membrane interactions, mGCR).
- Discussion of emerging research on secondary non-genomic effects and pre-receptor metabolism.
- Analysis of the dose-dependent relationship between GC mechanisms and clinical outcomes.
Main Results:
- GCs exert effects via cytosolic (cGCR) and membrane-bound (mGCR) receptors, involving classical genomic, non-specific non-genomic, and secondary non-genomic pathways.
- Adverse effects, such as metabolic issues and osteoporosis, are linked to the pleiotropic nature of GCs and their dose-dependent actions.
- Low-dose endogenous glucocorticoid immunostimulatory effects and pre-receptor metabolism warrant further investigation.
Conclusions:
- A comprehensive understanding of the molecular mechanisms of GC action, encompassing both genomic and non-genomic pathways and their dose-dependency, is crucial.
- Developing optimized glucocorticoids, like selective agonists, aims to minimize adverse effects while retaining therapeutic efficacy.
- Further research into nuanced GC actions, including low-dose effects and metabolism, is essential for improving patient outcomes and the overall risk-benefit profile.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Cushing Syndrome II: Pathophysiology
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Hormones of the Adrenal Glands
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and corticosterone...
